Politics
Colorado Activists File Revised Ballot Initiatives To Legalize Psilocybin And Establish ‘Healing Centers’
Colorado activists have filed revised versions of a pair of 2022 ballot initiatives to legalize psilocybin and create licensed “healing centers” where people can use the psychedelic for therapeutic purposes. The move comes as state lawmakers have introduced a separate bill to require a study into the efficacy of plant-based psychedelics.
The ballot measures—filed by Kevin Matthews, the campaign manager behind Denver’s historic 2019 vote to locally decriminalize psilocybin and entrepreneur Veronica Perez—are similar to earlier versions the advocates filed with the secretary of state’s office last month, with a few key changes concerning the rollout of the reform, promoting equity and possession limits.
For the original initiatives, the campaign was considering two options: one would have legalized a wide range of entheogenic substances including DMT, ibogaine and mescaline, as well as establish a regulatory model for psychedelics therapy. The other would have initially enacted the reform for psilocybin and psilocin alone.
But recognizing that regulators would be faced with an onerous task to set up rules for multiple psychedelics, activists decided to take a different approach with the new measures. For both, there would be a two-tiered regulatory model, where only psilocybin would be legalized and regulated for therapeutic use until June 2026, after which point regulators could expand the policy change to include other psychedelics that are listed in the proposal.
“We really wanted to make sure that the administration had time to set up a proper regulatory structure—first for psilocybin and then for any further natural medicines,” Rick Ridder of RBI Strategies, a spokesperson for the campaign, told Marijuana Moment on Monday.
The decision to add additional psychedelics to the program would be made by the Department of Regulatory Agencies in consultation with a Natural Medicine Advisory Board that would be established. The board would be comprised of 15 members, including people who have experience with psychedelic medicine in a scientific and religious context.
Another major change from the prior versions is that the revised initiatives do not contain explicit “allowable” possession limits—a provision that had garnered pushback from certain Colorado activists when the original measures were filed.
And unlike the last two versions of the initiatives, these new measures also include specific provisions meant to “ensure the regulatory access program is equitable and inclusive and to promote the licensing of and the provision of natural medicine services” for people who have been disproportionately impacted by drug criminalization, who face challenges accessing health care, have “traditional or indigenous history with natural medicines” and military veterans.
Those rules could involve, but are not limited to, reduced licensing fees, reduced costs for low-income people and an annual review of “the effectiveness of such policies and programs.”
“I think what this is is a giant step forward for mental health treatment in the state of Colorado,” Ridder said. “As we’ve looked at the results of research throughout the world, we’re seeing very promising data related to particularly healthy people with PTSD, with suicidal tendencies and end-of-life. And this is just an opportunity to bring that kind of natural medicine and medicinal help to citizens here in Colorado.”
The two new initiatives are nearly identical to each other, except that one contains a component specifically authorizing people to petition courts for record sealing for past convictions that would be made legal under the proposal.
Under the proposals, the Department of Regulatory Agencies would be responsible for developing rules for a therapeutic psychedelics program where adults 21 and older could visit a licensed “healing center” to receive treatment under the guidance of a trained facilitator.
This latest filing comes more than two years after Denver became the first city in the U.S. to decriminalize psilocybin mushrooms. Various activists, including those involved in the 2019 campaign, have signaled interest in building upon the reform.
The initiatives must still be assigned an official ballot title and summary from the state before they’re approved to begin signature gathering. The measures are scheduled to receive a review and comment hearing on February 3. If approved by state officials, activists will choose one of the measures to pursue and will then need to collect 124,632 valid signatures from registered voters to achieve ballot access.
The Colorado ballot initiatives seek to accomplish something similar to what California activists are actively pursuing. California advocates are in the process of collecting signatures for a ballot initiative to legalize psilocybin mushrooms in the state.
Meanwhile, in Colorado, Sen. Joann Ginal (D) and Rep. Alex Valdez (D) filed a modest bill last week to create a one-year plant-based medicine policy review panel that would be tasked with studying the “use of plant-based medicines to support mental health,” according to a summary. The ballot campaign is not affiliated with that legislative effort.
—
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
“The policy review panel shall submit a report on its findings and policy recommendations to the House of Representatives Public and Behavioral Health and Human Services Committee and the Senate Health and Human Services Committee, or any successor committees; the governor; and the Department of Human Services,” it says.
Meanwhile, legislative efforts to enact psychedelics reform are also underway in other states across the country.
For example, a bill to decriminalize a wide array of psychedelics in Virginia was taken up by a House of Delegates panel on Monday, only to be pushed off until 2023. But there’s still a separate but similar reform proposal that’s pending in the Senate.
Two Republican Oklahoma lawmakers recently filed bills meant to promote research into the therapeutic potential of psilocybin, and one of the measures would further decriminalize low-level possession of the psychedelic.
A GOP Utah lawmaker also introduced a bill last week that would set up a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use.
In Kansas, A lawmaker also recently filed a bill to legalize the low-level possession and cultivation of psilocybin mushrooms.
A Republican Missouri lawmaker introduced a bill this month to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD through an expanded version of the state’s existing right-to-try law.
California Sen. Scott Wiener (D) told Marijuana Moment in a recent interview that his bill to legalize psychedelics possession stands a 50/50 chance of reaching the governor’s desk this year. It already cleared the full Senate and two Assembly committees during the first half of the two-year session.
In Michigan, a pair of state senators introduced a bill in September to legalize the possession, cultivation and delivery of various plant- and fungi-derived psychedelics like psilocybin and mescaline.
Washington State lawmakers also introduced legislation this month that would legalize what the bill calls “supported psilocybin experiences” by adults 21 and older.
In Vermont, a broad coalition of lawmakers representing nearly a third of the House introduced a bill to decriminalize drug possession.
New Hampshire lawmakers filed measures to decriminalize psilocybin and all drugs.
Last year, the governor of Connecticut signed legislation that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
At the congressional level, bipartisan lawmakers sent a letter to the Drug Enforcement Administration (DEA) this month, urging that the agency allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.
Photo courtesy of Dick Culbert.